Medicine
Imitrex 25 mg tablet
Imitrex 25 mg tablet is a prescription medicine containing Sumatriptan for oral use, marketed by GlaxoSmithKline, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store between 2°C and 30°C (36°F and 86°F).
Key facts
- Active ingredient (INN)
- Sumatriptan
- Brand
- Imitrex
- Strength
- 25 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 1 carton
- Marketing authorisation holder
- GlaxoSmithKline
- Manufacturer
- GlaxoSmithKline
- Origin register
- US FDA, United States
- Storage
- Store between 2°C and 30°C (36°F and 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N02CC01 Sumatriptan
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 17 December 2003
- Identifiers
- RxCUI 208450, 209169, 284460 +3DailyMed set ID 584abe73-8290-4484-ff8e-5890831c095eNDC 0173-0735Application NDA020132
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 carton in 1 carton / 1 blister pack in 1 carton / 9 tablet, film coated in 1 blister pack | 0173-0735-00 | GlaxoSmithKline | 17 December 2003 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 28 December 1992 | Drugs@FDA |
| EU (EMA) | Refused | EMA medicines data |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Sumatriptan 25 mg tablet.
Other strengths and forms of Sumatriptan
Clinical summary
Sumatriptan is a serotonin-1b and serotonin-1d receptor agonist indicated in adults for the acute treatment of migraine, with or without aura, and the acute treatment of cluster headache, among other approved uses. MedsAcross supplies Sumatriptan for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SumatriptanFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- IMITREX prescribing information (GlaxoSmithKline) · U.S. National Library of Medicine, DailyMed
Need Imitrex 25 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.